File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Storage stability of lysostaphin solution and its pulmonary delivery

TitleStorage stability of lysostaphin solution and its pulmonary delivery
Authors
KeywordsBacterial lung infections
Bacteriolytic enzyme
Inhalation therapy
MRSA
Multidrug-resistant bacteria
Peptidoglycan
Issue Date17-Jan-2024
PublisherSpringer
Citation
Drug Delivery and Translational Research, 2024 How to Cite?
Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) has become a leading causative pathogen of nosocomial pneumonia with an alarming in-hospital mortality rate of 30%. Last resort antibiotic, vancomycin, has been increasingly used to treat MRSA infections, but the rapid emergence of vancomycin-resistant strains urges the development of alternative treatment strategies against MRSA-associated pneumonia. The bacteriolytic enzyme, lysostaphin, targeting the cell wall peptidoglycan of S. aureus, has been considered as a promising alternative for MRSA infections. Its proteinaceous nature is likely benefit from direct delivery to the lungs, but the challenges for successful pulmonary delivery of lysostaphin lying on a suitable inhalation device and a formulation with sufficient storage stability. In this study, the applicability of a vibrating mesh nebulizer (Aerogen Solo®) and a soft mist inhaler (Respimat®) was investigated. Both devices were capable of aerosolizing lysostaphin solution into inhalable droplets and caused minimum antibacterial activity loss. In addition, lysostaphin stabilized with phosphate-buffered saline and 0.1% Tween 80 was proved to have acceptable stability for at least 12 months when stored at 4 °C. These promising data encourage further clinical development of lysostaphin for management of MRSA-associated lung infections.


Persistent Identifierhttp://hdl.handle.net/10722/339698
ISSN
2023 Impact Factor: 5.7
2023 SCImago Journal Rankings: 0.994
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorZeng, Ping-
dc.contributor.authorZhang, Pengfei-
dc.contributor.authorChan, Ho Wan-
dc.contributor.authorChow, Shing Fung-
dc.contributor.authorLam, Jenny Ka Wing-
dc.contributor.authorIp, Margaret-
dc.contributor.authorLeung, Sharon Shui Yee-
dc.date.accessioned2024-03-11T10:38:40Z-
dc.date.available2024-03-11T10:38:40Z-
dc.date.issued2024-01-17-
dc.identifier.citationDrug Delivery and Translational Research, 2024-
dc.identifier.issn2190-393X-
dc.identifier.urihttp://hdl.handle.net/10722/339698-
dc.description.abstract<p>Methicillin-resistant <em>Staphylococcus aureus</em> (MRSA) has become a leading causative pathogen of nosocomial pneumonia with an alarming in-hospital mortality rate of 30%. Last resort antibiotic, vancomycin, has been increasingly used to treat MRSA infections, but the rapid emergence of vancomycin-resistant strains urges the development of alternative treatment strategies against MRSA-associated pneumonia. The bacteriolytic enzyme, lysostaphin, targeting the cell wall peptidoglycan of <em>S. aureus</em>, has been considered as a promising alternative for MRSA infections. Its proteinaceous nature is likely benefit from direct delivery to the lungs, but the challenges for successful pulmonary delivery of lysostaphin lying on a suitable inhalation device and a formulation with sufficient storage stability. In this study, the applicability of a vibrating mesh nebulizer (Aerogen Solo<sup>®</sup>) and a soft mist inhaler (Respimat<sup>®</sup>) was investigated. Both devices were capable of aerosolizing lysostaphin solution into inhalable droplets and caused minimum antibacterial activity loss. In addition, lysostaphin stabilized with phosphate-buffered saline and 0.1% Tween 80 was proved to have acceptable stability for at least 12 months when stored at 4 °C. These promising data encourage further clinical development of lysostaphin for management of MRSA-associated lung infections.<br></p>-
dc.languageeng-
dc.publisherSpringer-
dc.relation.ispartofDrug Delivery and Translational Research-
dc.subjectBacterial lung infections-
dc.subjectBacteriolytic enzyme-
dc.subjectInhalation therapy-
dc.subjectMRSA-
dc.subjectMultidrug-resistant bacteria-
dc.subjectPeptidoglycan-
dc.titleStorage stability of lysostaphin solution and its pulmonary delivery-
dc.typeArticle-
dc.identifier.doi10.1007/s13346-024-01518-9-
dc.identifier.scopuseid_2-s2.0-85182450117-
dc.identifier.eissn2190-3948-
dc.identifier.isiWOS:001142900300001-
dc.identifier.issnl2190-393X-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats